Compile Data Set for Download or QSAR
Report error Found 89 Enz. Inhib. hit(s) with all data for entry = 50009759
TargetKappa-type opioid receptor(Human)
The Scripps Research Institute

Curated by ChEMBL
LigandPNGBDBM50531921(US10676469, Compound 148 | CHEMBL4544914 | US11124...)
Affinity DataIC50: 0.260nMAssay Description:Antagonist activity at GAL4-VP16-fused KOR (unknown origin) expressed in human U2OS cells co-expressing Tango-OPRK1-BLA assessed as inhibition of U-5...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetKappa-type opioid receptor(Human)
The Scripps Research Institute

Curated by ChEMBL
LigandPNGBDBM50531915(US10676469, Compound 144 | CHEMBL4440683 | US11124...)
Affinity DataIC50: 0.530nMAssay Description:Antagonist activity at GAL4-VP16-fused KOR (unknown origin) expressed in human U2OS cells co-expressing Tango-OPRK1-BLA assessed as inhibition of U-5...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetKappa-type opioid receptor(Human)
The Scripps Research Institute

Curated by ChEMBL
LigandPNGBDBM50531910(CHEMBL4576339)
Affinity DataIC50: 0.590nMAssay Description:Antagonist activity at GAL4-VP16-fused KOR (unknown origin) expressed in human U2OS cells co-expressing Tango-OPRK1-BLA assessed as inhibition of U-5...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetKappa-type opioid receptor(Human)
The Scripps Research Institute

Curated by ChEMBL
LigandPNGBDBM50531909(CHEMBL4523014)
Affinity DataIC50: 0.760nMAssay Description:Antagonist activity at GAL4-VP16-fused KOR (unknown origin) expressed in human U2OS cells co-expressing Tango-OPRK1-BLA assessed as inhibition of U-5...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetKappa-type opioid receptor(Human)
The Scripps Research Institute

Curated by ChEMBL
LigandPNGBDBM50531911(CHEMBL4459625)
Affinity DataIC50: 0.770nMAssay Description:Antagonist activity at GAL4-VP16-fused KOR (unknown origin) expressed in human U2OS cells co-expressing Tango-OPRK1-BLA assessed as inhibition of U-5...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetKappa-type opioid receptor(Human)
The Scripps Research Institute

Curated by ChEMBL
LigandPNGBDBM50531916(US10676469, Compound 145 | CHEMBL4456582 | US11124...)
Affinity DataIC50: 0.780nMAssay Description:Antagonist activity at GAL4-VP16-fused KOR (unknown origin) expressed in human U2OS cells co-expressing Tango-OPRK1-BLA assessed as inhibition of U-5...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetKappa-type opioid receptor(Human)
The Scripps Research Institute

Curated by ChEMBL
LigandPNGBDBM50531908(US10676469, Compound 142 | Btrx-335140 | CYM-53093...)
Affinity DataIC50: 0.800nMAssay Description:Antagonist activity at GAL4-VP16-fused KOR (unknown origin) expressed in human U2OS cells co-expressing Tango-OPRK1-BLA assessed as inhibition of U-5...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetKappa-type opioid receptor(Human)
The Scripps Research Institute

Curated by ChEMBL
LigandPNGBDBM50531919(US10676469, Compound 146 | CHEMBL4549826 | US11124...)
Affinity DataIC50: 0.880nMAssay Description:Antagonist activity at GAL4-VP16-fused KOR (unknown origin) expressed in human U2OS cells co-expressing Tango-OPRK1-BLA assessed as inhibition of U-5...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetKappa-type opioid receptor(Human)
The Scripps Research Institute

Curated by ChEMBL
LigandPNGBDBM50531907(US10676469, Compound 141 | CHEMBL4583245 | US11124...)
Affinity DataIC50: 1.10nMAssay Description:Antagonist activity at GAL4-VP16-fused KOR (unknown origin) expressed in human U2OS cells co-expressing Tango-OPRK1-BLA assessed as inhibition of U-5...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetKappa-type opioid receptor(Human)
The Scripps Research Institute

Curated by ChEMBL
LigandPNGBDBM156575(US9682966, 355 | US10118915, Compound 355)
Affinity DataIC50: 1.30nMAssay Description:Antagonist activity at GAL4-VP16-fused KOR (unknown origin) expressed in human U2OS cells co-expressing Tango-OPRK1-BLA assessed as inhibition of U-5...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetKappa-type opioid receptor(Human)
The Scripps Research Institute

Curated by ChEMBL
LigandPNGBDBM159083(US9682966, 542 | US10118915, Compound 542)
Affinity DataIC50: 1.30nMAssay Description:Antagonist activity at GAL4-VP16-fused KOR (unknown origin) expressed in human U2OS cells co-expressing Tango-OPRK1-BLA assessed as inhibition of U-5...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetKappa-type opioid receptor(Human)
The Scripps Research Institute

Curated by ChEMBL
LigandPNGBDBM156541(US9682966, 324 | US10118915, Compound 324)
Affinity DataIC50: 1.30nMAssay Description:Antagonist activity at GAL4-VP16-fused KOR (unknown origin) expressed in human U2OS cells co-expressing Tango-OPRK1-BLA assessed as inhibition of U-5...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetKappa-type opioid receptor(Human)
The Scripps Research Institute

Curated by ChEMBL
LigandPNGBDBM50531912(CHEMBL4572131)
Affinity DataIC50: 1.5nMAssay Description:Antagonist activity at GAL4-VP16-fused KOR (unknown origin) expressed in human U2OS cells co-expressing Tango-OPRK1-BLA assessed as inhibition of U-5...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetKappa-type opioid receptor(Human)
The Scripps Research Institute

Curated by ChEMBL
LigandPNGBDBM50531908(US10676469, Compound 142 | Btrx-335140 | CYM-53093...)
Affinity DataKi:  1.5nMAssay Description:Displacement of [3H]diprenorphine from human KORMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetKappa-type opioid receptor(Human)
The Scripps Research Institute

Curated by ChEMBL
LigandPNGBDBM50531904(CHEMBL4540091)
Affinity DataIC50: 1.70nMAssay Description:Antagonist activity at GAL4-VP16-fused KOR (unknown origin) expressed in human U2OS cells co-expressing Tango-OPRK1-BLA assessed as inhibition of U-5...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetKappa-type opioid receptor(Human)
The Scripps Research Institute

Curated by ChEMBL
LigandPNGBDBM50531906(CHEMBL4443303 | US11124504, Cpd. No. 253)
Affinity DataIC50: 2.10nMAssay Description:Antagonist activity at GAL4-VP16-fused KOR (unknown origin) expressed in human U2OS cells co-expressing Tango-OPRK1-BLA assessed as inhibition of U-5...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetKappa-type opioid receptor(Human)
The Scripps Research Institute

Curated by ChEMBL
LigandPNGBDBM157256(US9682966, 433 | US10118915, Compound 433)
Affinity DataIC50: 2.20nMAssay Description:Antagonist activity at GAL4-VP16-fused KOR (unknown origin) expressed in human U2OS cells co-expressing Tango-OPRK1-BLA assessed as inhibition of U-5...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetKappa-type opioid receptor(Human)
The Scripps Research Institute

Curated by ChEMBL
LigandPNGBDBM50531905(US10676469, Compound 251 | CHEMBL4566736 | US11124...)
Affinity DataIC50: 2.30nMAssay Description:Antagonist activity at GAL4-VP16-fused KOR (unknown origin) expressed in human U2OS cells co-expressing Tango-OPRK1-BLA assessed as inhibition of U-5...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetKappa-type opioid receptor(Human)
The Scripps Research Institute

Curated by ChEMBL
LigandPNGBDBM50531914(US10676469, Compound 252 | CHEMBL4525666 | US11124...)
Affinity DataIC50: 2.40nMAssay Description:Antagonist activity at GAL4-VP16-fused KOR (unknown origin) expressed in human U2OS cells co-expressing Tango-OPRK1-BLA assessed as inhibition of U-5...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetKappa-type opioid receptor(Human)
The Scripps Research Institute

Curated by ChEMBL
LigandPNGBDBM156439(US9682966, 233 | US10118915, Compound 233)
Affinity DataIC50: 3nMAssay Description:Antagonist activity at GAL4-VP16-fused KOR (unknown origin) expressed in human U2OS cells co-expressing Tango-OPRK1-BLA assessed as inhibition of U-5...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetKappa-type opioid receptor(Human)
The Scripps Research Institute

Curated by ChEMBL
LigandPNGBDBM50531913(US10676469, Compound 253 | CHEMBL4584410 | US11124...)
Affinity DataIC50: 3.60nMAssay Description:Antagonist activity at GAL4-VP16-fused KOR (unknown origin) expressed in human U2OS cells co-expressing Tango-OPRK1-BLA assessed as inhibition of U-5...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetKappa-type opioid receptor(Human)
The Scripps Research Institute

Curated by ChEMBL
LigandPNGBDBM50531920(US10676469, Compound A | CHEMBL4434885)
Affinity DataIC50: 4.5nMAssay Description:Antagonist activity at GAL4-VP16-fused KOR (unknown origin) expressed in human U2OS cells co-expressing Tango-OPRK1-BLA assessed as inhibition of U-5...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetKappa-type opioid receptor(Human)
The Scripps Research Institute

Curated by ChEMBL
LigandPNGBDBM156498(US9682966, 285 | US10118915, Compound 285)
Affinity DataIC50: 7nMAssay Description:Antagonist activity at GAL4-VP16-fused KOR (unknown origin) expressed in human U2OS cells co-expressing Tango-OPRK1-BLA assessed as inhibition of U-5...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetKappa-type opioid receptor(Human)
The Scripps Research Institute

Curated by ChEMBL
LigandPNGBDBM50531917(CHEMBL4441250)
Affinity DataIC50: 9.5nMAssay Description:Antagonist activity at GAL4-VP16-fused KOR (unknown origin) expressed in human U2OS cells co-expressing Tango-OPRK1-BLA assessed as inhibition of U-5...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetKappa-type opioid receptor(Human)
The Scripps Research Institute

Curated by ChEMBL
LigandPNGBDBM50531918(CHEMBL4444292)
Affinity DataIC50: 10nMAssay Description:Antagonist activity at GAL4-VP16-fused KOR (unknown origin) expressed in human U2OS cells co-expressing Tango-OPRK1-BLA assessed as inhibition of U-5...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetKappa-type opioid receptor(Human)
The Scripps Research Institute

Curated by ChEMBL
LigandPNGBDBM50012149(CHEMBL3264446 | US9682966, 105 | US10118915, Compo...)
Affinity DataIC50: 13nMAssay Description:Antagonist activity at GAL4-VP16-fused KOR (unknown origin) expressed in human U2OS cells co-expressing Tango-OPRK1-BLA assessed as inhibition of U-5...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetMu-type opioid receptor(Human)
The Scripps Research Institute

Curated by ChEMBL
LigandPNGBDBM159083(US9682966, 542 | US10118915, Compound 542)
Affinity DataIC50: 31nMAssay Description:Antagonist activity at GAL4-VP16-fused MOR (unknown origin) expressed in human U2OS cells assessed as inhibition of DAMGO-induced beta-arrestin migra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetMu-type opioid receptor(Human)
The Scripps Research Institute

Curated by ChEMBL
LigandPNGBDBM156439(US9682966, 233 | US10118915, Compound 233)
Affinity DataIC50: 79nMAssay Description:Antagonist activity at GAL4-VP16-fused MOR (unknown origin) expressed in human U2OS cells assessed as inhibition of DAMGO-induced beta-arrestin migra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetMu-type opioid receptor(Human)
The Scripps Research Institute

Curated by ChEMBL
LigandPNGBDBM50531921(US10676469, Compound 148 | CHEMBL4544914 | US11124...)
Affinity DataIC50: 100nMAssay Description:Antagonist activity at GAL4-VP16-fused MOR (unknown origin) expressed in human U2OS cells assessed as inhibition of DAMGO-induced beta-arrestin migra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetMu-type opioid receptor(Human)
The Scripps Research Institute

Curated by ChEMBL
LigandPNGBDBM50531908(US10676469, Compound 142 | Btrx-335140 | CYM-53093...)
Affinity DataIC50: 110nMAssay Description:Antagonist activity at GAL4-VP16-fused MOR (unknown origin) expressed in human U2OS cells assessed as inhibition of DAMGO-induced beta-arrestin migra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetMu-type opioid receptor(Human)
The Scripps Research Institute

Curated by ChEMBL
LigandPNGBDBM156541(US9682966, 324 | US10118915, Compound 324)
Affinity DataIC50: 176nMAssay Description:Antagonist activity at GAL4-VP16-fused MOR (unknown origin) expressed in human U2OS cells assessed as inhibition of DAMGO-induced beta-arrestin migra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetMu-type opioid receptor(Human)
The Scripps Research Institute

Curated by ChEMBL
LigandPNGBDBM156498(US9682966, 285 | US10118915, Compound 285)
Affinity DataIC50: 183nMAssay Description:Antagonist activity at GAL4-VP16-fused MOR (unknown origin) expressed in human U2OS cells assessed as inhibition of DAMGO-induced beta-arrestin migra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetMu-type opioid receptor(Human)
The Scripps Research Institute

Curated by ChEMBL
LigandPNGBDBM50012149(CHEMBL3264446 | US9682966, 105 | US10118915, Compo...)
Affinity DataIC50: 323nMAssay Description:Antagonist activity at GAL4-VP16-fused MOR (unknown origin) expressed in human U2OS cells assessed as inhibition of DAMGO-induced beta-arrestin migra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetMu-type opioid receptor(Human)
The Scripps Research Institute

Curated by ChEMBL
LigandPNGBDBM50531915(US10676469, Compound 144 | CHEMBL4440683 | US11124...)
Affinity DataIC50: 400nMAssay Description:Antagonist activity at GAL4-VP16-fused MOR (unknown origin) expressed in human U2OS cells assessed as inhibition of DAMGO-induced beta-arrestin migra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetKappa-type opioid receptor(Human)
The Scripps Research Institute

Curated by ChEMBL
LigandPNGBDBM50012148(CHEMBL3183148)
Affinity DataIC50: 410nMAssay Description:Antagonist activity at GAL4-VP16-fused KOR (unknown origin) expressed in human U2OS cells co-expressing Tango-OPRK1-BLA assessed as inhibition of U-5...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetMu-type opioid receptor(Human)
The Scripps Research Institute

Curated by ChEMBL
LigandPNGBDBM50531908(US10676469, Compound 142 | Btrx-335140 | CYM-53093...)
Affinity DataKi:  450nMAssay Description:Binding affinity to human MORMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetMu-type opioid receptor(Human)
The Scripps Research Institute

Curated by ChEMBL
LigandPNGBDBM50531910(CHEMBL4576339)
Affinity DataIC50: 583nMAssay Description:Antagonist activity at GAL4-VP16-fused MOR (unknown origin) expressed in human U2OS cells assessed as inhibition of DAMGO-induced beta-arrestin migra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetMu-type opioid receptor(Human)
The Scripps Research Institute

Curated by ChEMBL
LigandPNGBDBM157256(US9682966, 433 | US10118915, Compound 433)
Affinity DataIC50: 829nMAssay Description:Antagonist activity at GAL4-VP16-fused MOR (unknown origin) expressed in human U2OS cells assessed as inhibition of DAMGO-induced beta-arrestin migra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetPotassium voltage-gated channel subfamily H member 2(Human)
The Scripps Research Institute

Curated by ChEMBL
LigandPNGBDBM50531908(US10676469, Compound 142 | Btrx-335140 | CYM-53093...)
Affinity DataIC50: 1.00E+3nMAssay Description:Inhibition of human ERG expressed in HEK293 cells at 10 uM by Qpatch clamp assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetMu-type opioid receptor(Human)
The Scripps Research Institute

Curated by ChEMBL
LigandPNGBDBM50531916(US10676469, Compound 145 | CHEMBL4456582 | US11124...)
Affinity DataIC50: 1.10E+3nMAssay Description:Antagonist activity at GAL4-VP16-fused MOR (unknown origin) expressed in human U2OS cells assessed as inhibition of DAMGO-induced beta-arrestin migra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetMu-type opioid receptor(Human)
The Scripps Research Institute

Curated by ChEMBL
LigandPNGBDBM50531913(US10676469, Compound 253 | CHEMBL4584410 | US11124...)
Affinity DataIC50: 1.20E+3nMAssay Description:Antagonist activity at GAL4-VP16-fused MOR (unknown origin) expressed in human U2OS cells assessed as inhibition of DAMGO-induced beta-arrestin migra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetMu-type opioid receptor(Human)
The Scripps Research Institute

Curated by ChEMBL
LigandPNGBDBM50531907(US10676469, Compound 141 | CHEMBL4583245 | US11124...)
Affinity DataIC50: 1.40E+3nMAssay Description:Antagonist activity at GAL4-VP16-fused MOR (unknown origin) expressed in human U2OS cells assessed as inhibition of DAMGO-induced beta-arrestin migra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetMu-type opioid receptor(Human)
The Scripps Research Institute

Curated by ChEMBL
LigandPNGBDBM50531919(US10676469, Compound 146 | CHEMBL4549826 | US11124...)
Affinity DataIC50: 1.40E+3nMAssay Description:Antagonist activity at GAL4-VP16-fused MOR (unknown origin) expressed in human U2OS cells assessed as inhibition of DAMGO-induced beta-arrestin migra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetMu-type opioid receptor(Human)
The Scripps Research Institute

Curated by ChEMBL
LigandPNGBDBM50531911(CHEMBL4459625)
Affinity DataIC50: 1.46E+3nMAssay Description:Antagonist activity at GAL4-VP16-fused MOR (unknown origin) expressed in human U2OS cells assessed as inhibition of DAMGO-induced beta-arrestin migra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetMu-type opioid receptor(Human)
The Scripps Research Institute

Curated by ChEMBL
LigandPNGBDBM50531912(CHEMBL4572131)
Affinity DataIC50: 1.50E+3nMAssay Description:Antagonist activity at GAL4-VP16-fused MOR (unknown origin) expressed in human U2OS cells assessed as inhibition of DAMGO-induced beta-arrestin migra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetDelta-type opioid receptor(Human)
The Scripps Research Institute

Curated by ChEMBL
LigandPNGBDBM159083(US9682966, 542 | US10118915, Compound 542)
Affinity DataIC50: 2.41E+3nMAssay Description:Antagonist activity at GAL4-VP16-fused DOR (unknown origin) expressed in human U2OS cells assessed as inhibition of DAMGO-induced beta-arrestin migra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetMu-type opioid receptor(Human)
The Scripps Research Institute

Curated by ChEMBL
LigandPNGBDBM50531904(CHEMBL4540091)
Affinity DataIC50: 2.93E+3nMAssay Description:Antagonist activity at GAL4-VP16-fused MOR (unknown origin) expressed in human U2OS cells assessed as inhibition of DAMGO-induced beta-arrestin migra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetMu-type opioid receptor(Human)
The Scripps Research Institute

Curated by ChEMBL
LigandPNGBDBM50531909(CHEMBL4523014)
Affinity DataIC50: 3.33E+3nMAssay Description:Antagonist activity at GAL4-VP16-fused MOR (unknown origin) expressed in human U2OS cells assessed as inhibition of DAMGO-induced beta-arrestin migra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetDelta-type opioid receptor(Human)
The Scripps Research Institute

Curated by ChEMBL
LigandPNGBDBM50012149(CHEMBL3264446 | US9682966, 105 | US10118915, Compo...)
Affinity DataIC50: 3.50E+3nMAssay Description:Antagonist activity at GAL4-VP16-fused DOR (unknown origin) expressed in human U2OS cells assessed as inhibition of DAMGO-induced beta-arrestin migra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetMu-type opioid receptor(Human)
The Scripps Research Institute

Curated by ChEMBL
LigandPNGBDBM156575(US9682966, 355 | US10118915, Compound 355)
Affinity DataIC50: 4.39E+3nMAssay Description:Antagonist activity at GAL4-VP16-fused MOR (unknown origin) expressed in human U2OS cells assessed as inhibition of DAMGO-induced beta-arrestin migra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
Displayed 1 to 50 (of 89 total ) | Next | Last >>
Jump to: